Innate Pharma (IPHA) Shares Outstanding (2019 - 2025)

Innate Pharma has reported Shares Outstanding for 7 years, with the latest figure at $109.1 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding rose 21.78% year-over-year to $109.1 million; the trailing twelve-month figure through Dec 2025 stood at $109.1 million (up 21.78% YoY), and the FY2025 full-year result was $109.1 million, up 21.78% from the prior year.
• Shares Outstanding for Q4 2025 stood at $109.1 million, up from $89.6 million in the prior quarter.
• The five-year high for Shares Outstanding was $109.1 million in Q4 2025, with the low at $81.2 million in Q4 2022.
• Historically, Shares Outstanding has averaged $91.5 million across 5 years, with a median of $89.6 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding dropped 10.82% — and 2025, when it grew 21.78%.
• Innate Pharma's Shares Outstanding stood at $91.0 million in 2021, then slipped by 10.82% to $81.2 million in 2022, then rose by 6.67% to $86.6 million in 2023, then gained by 3.49% to $89.6 million in 2024, then climbed by 21.78% to $109.1 million in 2025.
• The last three Shares Outstanding figures came in at $109.1 million (Q4 2025), $89.6 million (Q4 2024), and $86.6 million (Q4 2023), per Business Quant data.